American Journal of Transplantation

Article	Citations
COVID-19 in solid organ transplant recipients: Initial report from the US epicenter	617
The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection	434
COVID-19 in solid organ transplant recipients: A single-center case series from Spain	325
COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium	289
OPTN/SRTR 2019 Annual Data Report: Kidney	275
Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus	274
OPTN/SRTR 2019 Annual Data Report: Liver	235
Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression	234
OPTN/SRTR 2020 Annual Data Report: Liver	212
First clinical-grade porcine kidney xenotransplant using a human decedent model	206
Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?	200
Decreased influenza activity during the COVID-19 pandemic—United States, Australia, Chile, and South Africa, 2020	190
COVID-19 in kidney transplant recipients	189
OPTN/SRTR 2020 Annual Data Report: Kidney	189
Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients	187
Early impact of COVID-19 on transplant center practices and policies in the United States	187
Is COVID-19 infection more severe in kidney transplant recipients?	179
COVID-19: A global transplant perspective on successfully navigating a pandemic	170
COVID-19 in kidney transplant recipients	154
Iron overload as a risk factor for hepatic ischemia-reperfusion injury in liver transplantation: Potential role of ferroptosis	149
COVID-19 in transplant recipients: The Spanish experience	137
Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation	133
Coronavirus disease 2019: Implications of emerging infections for transplantation	129
The COVID-19 outbreak in Italy: Initial implications for organ transplantation programs	125
OPTN/SRTR 2019 Annual Data Report: Lung	123

SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: A national cohort study	122
Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation–Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation	117
Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients	117
A change of heart: Preliminary results of the US 2018 adult heart allocation revision	111
Clinical characteristics and outcomes of COVID-19 in solid organ transplant recipients: A cohort study	111
Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients	110
OPTN/SRTR 2020 Annual Data Report: Heart	109
Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients	107
Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients	107
Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing	103
Impact of COVID-19 in solid organ transplant recipients	96
COVID-19 in posttransplant patients—report of 2 cases	95
Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients	93
COVID-19 vaccination intent, perceptions, and reasons for not vaccinating among groups prioritized for early vaccination — United States, September and December 2020	93
First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study	91
Potential indirect effects of the COVID-19 pandemic on use of emergency departments for acute life-threatening conditions — United States, January–May 2020	91
OPTN/SRTR 2019 Annual Data Report: Heart	90
Maintaining the permanence principle for death during in situ normothermic regional perfusion for donation after circulatory death organ recovery: A United Kingdom and Canadian proposal	90
Long-term kidney transplant graft survival—Making progress when most needed	89
Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve	89
Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients	88
Liver transplantation for critically ill cirrhotic patients: Stratifying utility based on pretransplant factors	85
Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept	84
Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: A By-proxy Society Recommendation Consensus approach	82
Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review	82
Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States	82
Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave	81
High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury	81
Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients	77
Decline in child vaccination coverage during the COVID-19 pandemic — Michigan Care Improvement Registry, May 2016-May 2020	76
OPTN/SRTR 2020 Annual Data Report: Lung	76
Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients	76
A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: Lessons to be learned	76
Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience	74
Abdominal normothermic regional perfusion in controlled donation after circulatory determination of death liver transplantation: Outcomes and risk factors for graft loss	74
Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study	73
Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States	73
COVID-19 in Spain: Transplantation in the midst of the pandemic	73
Ischemia-reperfusion injury and its relationship with early allograft dysfunction in liver transplant patients	71
COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine	70
Use of SARS-CoV-2-infected deceased organ donors: Should we always “just say no?”	69
Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report	68
SARS Cov-2 infection in a renal-transplanted patient: A case report	68
Ten years of donor-derived disease: A report of the disease transmission advisory committee	67
Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement	67
Fatal outcome in a liver transplant recipient with COVID-19	67
Use of tocilizumab in kidney transplant recipients with COVID-19	66
PD-1 inhibitor as bridge therapy to liver transplantation?	66
Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies	66
Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: A therapeutical hypothesis	65

Donor-specific chimeric antigen receptor Tregs limit rejection in naive but not sensitized allograft recipients	65
Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes	64
Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients—A prospective observational trial	63
COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination	63
Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients	63
Kidney transplantation from triple-knockout pigs expressing multiple human proteins in cynomolgus macaques	62
COVID-19 outcomes in patients waitlisted for kidney transplantation and kidney transplant recipients	61
COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities	61
Sequential hypothermic and normothermic machine perfusion enables safe transplantation of high-risk donor livers	60
OPTN/SRTR 2021 Annual Data Report: Kidney	60
Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine	60
In-depth virological assessment of kidney transplant recipients with COVID-19	60
Early success transplanting kidneys from donors with new SARS-CoV-2 RNA positivity: A report of 10 cases	59
Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient	59
Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients	58
COVID-19 in elderly kidney transplant recipients	58
A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients	58
Incidence and outcome of SARS-CoV-2 infection on solid organ transplantation recipients: A nationwide population-based study	58
Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients	58
Hypothermic oxygenated perfusion in extended criteria donor liver transplantation—A randomized clinical trial	57
Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients	57
Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic	57
The impact of the COVID-19 outbreak on liver transplantation programs in Northern Italy	57
Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case report	56
OPTN/SRTR 2021 Annual Data Report: Liver	55
Coronavirus disease 2019 and transplantation: A view from the inside	55
Early national and center-level changes to kidney transplantation in the United States during the COVID-19 epidemic	54
Inpatient COVID-19 outcomes in solid organ transplant recipients compared to non-solid organ transplant patients: A retrospective cohort	54
Clinical importance of extended second field high-resolution HLA genotyping for kidney transplantation	54
Organ donation during the COVID-19 pandemic	54
Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge	53
Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants	53
Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States	53
Liver transplantation from active COVID-19 donors: A lifesaving opportunity worth grasping?	52
COVID-19 in lung transplant recipients: A single center case series from New York City	52
Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation	52
Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients	51
A case of coronavirus disease 2019–infected liver transplant donor	51
A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action	51
First case of COVID-19 in a kidney transplant recipient treated with belatacept	50
COVID-19 in lung transplant recipients: A multicenter study	50
A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation	50
Utilization of deceased donors during a pandemic: argument against using SARS-CoV-2–positive donors	49
Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry	49
Changes in influenza and other respiratory virus activity during the COVID-19 pandemic—United States, 2020–2021	49
Consensus conference on heart-kidney transplantation	49
A call to routinely test lower respiratory tract samples for SARS-CoV-2 in lung donors	48
Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2?	48
Immunosuppressive therapy maintenance in a kidney transplant recipient with SARS-CoV-2 pneumonia: A case report	48
Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study	46
RNA interference therapeutics in organ transplantation: The dawn of a new era	46
Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency	46
An international comparison of deceased donor kidney utilization: What can the United States and the United Kingdom learn from each other?	46
SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients	46
Substituting imputation of HLA antigens for high-resolution HLA typing: Evaluation of a multiethnic population and implications for clinical decision making in transplantation	45
Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement	45
OPTN/SRTR 2020 Annual Data Report: Pancreas	45
Novel delivery of cellular therapy to reduce ischemia reperfusion injury in kidney transplantation	45
Neighborhood socioeconomic deprivation is associated with worse patient and graft survival following pediatric liver transplantation	45
Identifying scenarios of benefit or harm from kidney transplantation during the COVID-19 pandemic: A stochastic simulation and machine learning study	45
Improved short-term outcomes of kidney transplants in controlled donation after the circulatory determination of death with the use of normothermic regional perfusion	45
Normothermic kidney perfusion: An overview of protocols and strategies	44
Greater complexity and monitoring of the new Kidney Allocation System: Implications and unintended consequences of concentric circle kidney allocation on network complexity	44
Prolonged preservation by hypothermic machine perfusion facilitates logistics in liver transplantation: A European observational cohort study	44
Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics	44
First-in-human use of a marine oxygen carrier (M101) for organ preservation: A safety and proof-of-principle study	44
Allograft infiltration and meningoencephalitis by SARS-CoV-2 in a pancreas-kidney transplant recipient	43
Dialysis facility referral and start of evaluation for kidney transplantation among patients treated with dialysis in the Southeastern United States	43
First World Consensus Conference on pancreas transplantation: Part II – recommendations	42
Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients	42
CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder	42
Cyclosporine and COVID-19: Risk or favorable?	42
Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients	42
White paper on antimicrobial stewardship in solid organ transplant recipients	42
Early liver transplantation after COVID-19 infection: The first report	42
Meta-analysis and meta-regression of outcomes for adult living donor liver transplantation versus deceased donor liver transplantation	42
Evidence for the alloimmune basis and prognostic significance of Borderline T cell–mediated rejection	42
Donor and transplant candidate selection for solid organ transplantation during the COVID-19 pandemic	42
Spanish experience with heart transplants from controlled donation after the circulatory determination of death using thoraco-abdominal normothermic regional perfusion and cold storage	41
Ethical and logistical concerns for establishing NRP-cDCD heart transplantation in the United States	41

CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept	41
mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients	40
Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic	40
Dismantling structural racism as a root cause of racial disparities in COVID-19 and transplantation	40
A familial cluster, including a kidney transplant recipient, of Coronavirus Disease 2019 (COVID-19) in Wuhan, China	40
Outcome of liver transplantation with grafts from brain-dead donors treated with dual hypothermic oxygenated machine perfusion, with particular reference to elderly donors	40
OPTN/SRTR 2019 Annual Data Report: Pancreas	40
Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation	40
First-in-man controlled rewarming and normothermic perfusion with cell-free solution of a kidney prior to transplantation	40
Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients	40
COVID-19 in pediatric kidney transplantation: The Improving Renal Outcomes Collaborative	40
Prevalence and predictors of SARS-CoV-2 antibodies among solid organ transplant recipients with confirmed infection	39
Between fear and courage: Attitudes, beliefs, and behavior of liver transplantation recipients and waiting list candidates during the COVID-19 pandemic	39
The negative impact of T cell–mediated rejection on renal allograft survival in the modern era	39
Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma	39
Obesity, transplantation, and bariatric surgery: An evolving solution for a growing epidemic	39
Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial	38
Navigating the COVID-19 pandemic: Initial impacts and responses of the Organ Procurement and Transplantation Network in the United States	38
Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection	38
Initial lung transplantation experience with uncontrolled donation after cardiac death in North America	38
The 2018 Banff Working Group classification of definitive polyomavirus nephropathy: A multicenter validation study in the modern era	38
COVID-19 in a high-risk dual heart and kidney transplant recipient	38
Liver transplantation performed in a SARS-CoV-2 positive hospitalized recipient using a SARS-CoV-2 infected donor	37
New French heart allocation system: Comparison with Eurotransplant and US allocation systems	37
Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients	37
Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021	37
Lysis of cold-storage-induced microvascular obstructions for ex vivo revitalization of marginal human kidneys	37
Cytokine absorption during human kidney perfusion reduces delayed graft function–associated inflammatory gene signature	36
T cell and antibody responses to SARS-CoV-2: Experience from a French transplantation and hemodialysis center during the COVID-19 pandemic	36
Viral shedding prolongation in a kidney transplant patient with COVID-19 pneumonia	36
Prevalence of frailty among kidney transplant candidates and recipients in the United States: Estimates from a National Registry and Multicenter Cohort Study	36
Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring	36
Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients	36
Butyric acid normalizes hyperglycemia caused by the tacrolimus-induced gut microbiota	36
Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020	36
In situ multiplex immunofluorescence analysis of the inflammatory burden in kidney allograft rejection: A new tool to characterize the alloimmune response	36
COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: A comparative analysis from a multicenter study	35
Pseudomonas aeruginosa and acute rejection independently increase the risk of donor-specific antibodies after lung transplantation	35
Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients	35
Guidelines for standardized nomenclature and reporting in uterus transplantation: An opinion from the United States Uterus Transplant Consortium	35
Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection	35
Successful orthotopic liver transplantation in a patient with a positive SARS-CoV2 test and acute liver failure secondary to acetaminophen overdose	35
OPTN/SRTR 2021 Annual Data Report: Lung	35
An early experience on the effect of solid organ transplant status on hospitalized COVID-19 patients	35
Early experience of COVID-19 in 2 heart transplant recipients: Case reports and review of treatment options	35
Racial disparities in preemptive waitlisting and deceased donor kidney transplantation: Ethics and solutions	35
Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial	34
Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation	34
Response to American College of Physician’s statement on the ethics of transplant after normothermic regional perfusion	34
COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era	34
COVID-19 in lung transplant patients: A case series	34
Validation of the Model for End-stage Liver Disease sodium (MELD-Na) score in the Eurotransplant region	34
Extracellular vesicles for treatment of solid organ ischemia–reperfusion injury	34
Banff Digital Pathology Working Group: Going digital in transplant pathology	34
Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report	34
Utilization and outcomes of deceased donor SARS-CoV-2–positive organs for solid organ transplantation in the United States	33
Mechanisms of organ transplant injury mediated by B cells and antibodies: Implications for antibody-mediated rejection	33
Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab	33
Ethical review of COVID-19 vaccination requirements for transplant center staff and patients	33
Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: The Neptune study, a phase I single-center study	33
Donor-derived regulatory dendritic cell infusion results in host cell cross-dressing and T cell subset changes in prospective living donor liver transplant recipients	33
Molecular phenotyping of rejection-related changes in mucosal biopsies from lung transplants	32
Brief O2 uploading during continuous hypothermic machine perfusion is simple yet effective oxygenation method to improve initial kidney function in a porcine autotransplant model	32
Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members — Chicago, Illinois, December 2020–March 2021	32
Liver transplantation in the United States during the COVID-19 pandemic: National and center-level responses	31
The demise of islet allotransplantation in the United States: A call for an urgent regulatory update	31
OPTN/SRTR 2019 Annual Data Report: Intestine	31
Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept	31
Mild COVID-19 in a pediatric renal transplant recipient	31
The molecular diagnosis of rejection in liver transplant biopsies: First results of the INTERLIVER study	31
Severe consequences of COVID-19 infection among vaccinated kidney transplant recipients	30
Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience	30
Factors associated with kidney graft survival in pure antibody-mediated rejection at the time of indication biopsy: Importance of parenchymal injury but not disease activity	30
Adequate tacrolimus exposure modulates the impact of HLA class II molecular mismatch: a validation study in an American cohort	30
Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning	30
Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020	30
Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation	30
Developing simultaneous liver-kidney transplant medical eligibility criteria while providing a safety net: A 2-year review of the OPTN’s allocation policy	30
Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: Not alarming, but should be taken gravely	30
Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation	30
Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients	30
Shielding islets with human amniotic epithelial cells enhances islet engraftment and revascularization in a murine diabetes model	30
COVID-19 in solid organ transplant recipients: A national cohort study from Sweden	29
Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study	29
A gut microbiota score predicting acute graft-versus-host disease following myeloablative allogeneic hematopoietic stem cell transplantation	29
Immunosuppressive therapy after solid organ transplantation and the gut microbiota: Bidirectional interactions with clinical consequences	29
Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: Differences in timing and intensity but similar mechanisms and outcomes	29
Two distinct cases with COVID-19 in kidney transplant recipients	29
Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study	29
Long-term shedding of viable SARS-CoV-2 in kidney transplant recipients with COVID-19	29
The impact of multi-organ transplant allocation priority on waitlisted kidney transplant candidates	29
Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-γ release assay in kidney transplant recipients treated with antithymocyte globulin	28
Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: Efficacy, ethnic and racial disparities	28
Discovery and validation of a novel blood-based molecular biomarker of rejection following liver transplantation	28
HOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV	28